| Fallopian Tube Carcinoma

Elahere vs Zirabev

Side-by-side clinical, coverage, and cost comparison for fallopian tube carcinoma.

Deep comparison between: Elahere vs Zirabev with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZirabev has a higher rate of injection site reactions vs Elahere based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zirabev but not Elahere, including UnitedHealthcare

Category

Elahere

Zirabev

At A Glance

RouteIV infusion

FrequencyEvery 3 weeks

ClassFRalpha-directed ADC

RouteIV infusion

FrequencyEvery 2-3 weeks

ClassVEGF inhibitor

Indications

Carcinoma, Ovarian Epithelial
Fallopian Tube Carcinoma
Primary Peritoneal Cancer

Metastasis from malignant neoplasm of colon and/or rectum
Non-Small Cell Lung Carcinoma
Glioblastoma
Renal Cell Carcinoma
Cervix carcinoma
Malignant neoplasm of ovary
Fallopian Tube Carcinoma
Primary Peritoneal Cancer

Dosing

Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer 6 mg/kg adjusted ideal body weight (AIBW) as an IV infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity; premedicate with a corticosteroid, antihistamine, antipyretic, and antiemetic prior to each infusion.

Metastasis from malignant neoplasm of colon and/or rectum 5 mg/kg IV every 2 weeks with bolus-IFL; 10 mg/kg IV every 2 weeks with FOLFOX4; 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy after progression on a first-line bevacizumab product-containing regimen.

Non-Small Cell Lung Carcinoma 15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel.

Glioblastoma 10 mg/kg IV every 2 weeks.

Renal Cell Carcinoma 10 mg/kg IV every 2 weeks in combination with interferon alfa.

Cervix carcinoma 15 mg/kg IV every 3 weeks in combination with paclitaxel and cisplatin or paclitaxel and topotecan.

Malignant neoplasm of ovary, Fallopian Tube Carcinoma, Primary Peritoneal Cancer Stage III/IV following initial surgical resection: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, followed by 15 mg/kg every 3 weeks as a single agent for up to 22 cycles. Platinum-resistant recurrent: 10 mg/kg IV every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg IV every 3 weeks with topotecan (every 3 weeks). Platinum-sensitive recurrent: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel or carboplatin and gemcitabine for 6-10 cycles, followed by 15 mg/kg every 3 weeks as a single agent.

Contraindications

—

Drug Interactions

219View drug interactions

232View drug interactions

Adverse Reactions

Most common (>=20%) increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, decreased neutrophils

Serious intestinal obstruction, abdominal pain, pleural effusion, ascites, infection, neutropenic sepsis, cardiopulmonary failure, respiratory failure, ischemic stroke, pulmonary embolus

Most common (>10%) Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis.

Serious Gastrointestinal perforations and fistulae, surgery and wound healing complications, hemorrhage, arterial thromboembolic events, venous thromboembolic events, hypertension, posterior reversible encephalopathy syndrome, renal injury and proteinuria, infusion-related reactions, ovarian failure, congestive heart failure.

Postmarketing Polyserositis, pulmonary hypertension, mesenteric venous occlusion, gastrointestinal ulcer, intestinal necrosis, anastomotic ulceration, pancytopenia, gallbladder perforation, osteonecrosis of the jaw, renal thrombotic microangiopathy, nasal septum perforation, arterial aneurysms/dissections/rupture.

Pharmacology

Mirvetuximab soravtansine-gynx is a folate receptor alpha (FRalpha)-directed antibody-drug conjugate (ADC) consisting of an anti-FRalpha chimeric IgG1 antibody linked via a cleavable sulfo-SPDB linker to DM4, a microtubule inhibitor; upon binding to FRalpha and internalization, DM4 is released intracellularly to disrupt the microtubule network, inducing cell cycle arrest and apoptotic cell death.

Bevacizumab-bvzr binds VEGF and prevents its interaction with receptors Flt-1 and KDR on the surface of endothelial cells, inhibiting endothelial cell proliferation, new blood vessel formation, and metastatic disease progression.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Elahere